Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study is testing a combination treatment using epcoritamab (an antibody-based immunotherapy) together with CAR T-cell therapy for people with large B-cell lymphoma — an aggressive blood cancer — that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with large B-cell lymphoma confirmed by a pathology report - Your cancer has relapsed (come back) or is refractory (not responding) to prior treatment - You are in good enough health to participate (ECOG 0–2) - You or your legal representative can provide informed consent **You may NOT be eligible if...** - Your lymphoma diagnosis is not confirmed by pathology - Your performance status is too poor - You are unable or unwilling to follow the study protocol Talk to your doctor to see if this trial is right for you.